Virtual Library
Start Your Search
Ichiro Yoshino
Author of
-
+
EP1.15 - Thymoma/Other Thoracic Malignancies (ID 205)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Thymoma/Other Thoracic Malignancies
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.15-05 - Surgical Outcomes of Pulmonary Metastasectomy for Head and Neck Cancer: A Single Institutional Retrospective Study (Now Available) (ID 2095)
08:00 - 18:00 | Author(s): Ichiro Yoshino
- Abstract
Background
Pulmonary metastasis is often observed during clinical course of head and neck cancer (HNC). Five-year survival rate after pulmonary metastasectomy of HNC has been reported to be around 60%, however, proper indication of metastasectomy remains unclear. We aimed to clarify clinicopathological features and surgical outcomes of HNC patients who underwent with pulmonary metastasectomy.
Method
A total of 25 patients underwent pulmonary metastasectomy at Chiba University Hospital during from January 2011 to December 2016. Prognostic factors related to overall survival after pulmonary metastasectomy were retrospectively examined using the univariable Cox proportional hazard models.
Result
Conclusion
Median follow-up period was 39.5 ±22.5 months. Mean age of the patients was 64.5 ±13.4 years, and they included 23 males. Primary lesions arose in pharynx in 12 patients, oral cavity and nasal cavity and paranasal cavity in 6, larynx in 4, and salivary gland in 3. Seventeen patients were diagnosed as stage IV due to tumor size and/or lymph node metastasis in the first presentation. Primary lesions were resected in 19 patients, and chemotherapy and/or radiation therapy were added in 15 out of these patients. The mean tumor diameter of pulmonary metastases was 15.4 ±10.3 mm. A single pulmonary nodule was detected in 15 patients and double in 6, triple in 3 and four in 1 patient, respectively. Among the 40 lesions, partial resection was selected for 30, segmentectomy for 7, lobectomy for 3. Squamous cell carcinoma was the most predominant (76%). Recurrent site after pulmonary metastasectomy was most frequently observed in the lung (72%). Eight patients survived without recurrence, 10 patients survived with recurrent disease, and others died of the diseases. After pulmonary recurrence, 3 patients underwent repeated metastasectomy, and eventually achieved cancer free status for 4.43 ±1.64 years. Following pulmonary metastasectomy, 6 patients were suffered from other cancers. Three- and 5-year survival rates were 81.7% and 47.5%, respectively. In the univariate analysis, disease free survival (< 140 days) and age (< 60) were independent predictors of poor prognosis.
Surgical treatment for pulmonary metastasis of HNC can offer favorable survival. The number of cancer-bearing patients after pulmonary metastasectomy is increasing possibly due to the advance of novel chemotherapy. It is important to provide a careful observation considering that the most frequent site to redevelop recurrence after pulmonary metastasectomy is the lung and that other organ cancers often arise in those patients.
